TACSTD2 and neoplasm: Although there was no difference in post-ICI response in CRC or hepatocellular cancer, further exploration of TACSTD2’s relationship with the tumor immune microenvironment as well as combination approaches of ICI and TROP2 ADC in TROP2+/TACSTD2-high tumors may be merited.